Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Alessandro Cherubini, Elia Casirati, Melissa Tomasi, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 12, pp. 1033-1043
Open Access | Times Cited: 54

Showing 26-50 of 54 citing articles:

PNPLA3 I148M and Hepatocellular Carcinoma
Federica Tavaglione, Grazia Pennisi, Serena Pelusi
Liver International (2025) Vol. 45, Iss. 4
Open Access
Association of PNPLA3 rs738409 C > G and rs2896019 T > G Polymorphisms with Nonalcoholic Fatty Liver Disease in a Turkish Population from Adıyaman Province
Süleyman Bayram, Yakup Ülger
Genetic Testing and Molecular Biomarkers (2025) Vol. 29, Iss. 3, pp. 63-73
Closed Access
Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD
Giovanna Mercurio, Antonia Giacco, Nicla Scopigno, et al.
Nutrients (2025) Vol. 17, Iss. 7, pp. 1214-1214
Open Access
Evaluation of Metabolic Dysfunction-Associated Fatty Liver Disease-Related Pathogenic Mechanisms in Human Steatotic Liver Cell-Based Model: Beneficial Effects of Prunus domestica L. subsp. syriaca Extract
Laura Comi, Claudia Giglione, Fationa Tolaj, et al.
Nutrients (2025) Vol. 17, Iss. 7, pp. 1249-1249
Open Access
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Mohadeseh Poudineh, Fatemeh Mohammadyari, Negin Parsamanesh, et al.
Gene (2025), pp. 149466-149466
Closed Access
Intestinal Activation of LXRα Counteracts Metabolic-Associated Steatohepatitis Features in Mice
Gessica Lioci, Fabio Gurrado, Nadia Panera, et al.
Nutrients (2025) Vol. 17, Iss. 8, pp. 1349-1349
Open Access
PNPLA3 in largemouth bass (Micropterus salmoides): Molecular cloning, functional characterization, and its role in high glucose-induced lipid synthesis
Yanbin Yang, Yingying Xu, Hao Ding, et al.
Aquaculture Reports (2025) Vol. 42, pp. 102821-102821
Closed Access
Gene-based therapies for steatotic liver disease
Viktoriia Iakovleva, Ype P. de Jong
Molecular Therapy (2025)
Closed Access
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Ikki Sakuma, Rafael Calais Gaspar, Ali Nasiri, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 18
Open Access
A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease
Nuria Pérez-Díaz-del-Campo, Eleonora Dileo, Gabriele Castelnuovo, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 11, pp. 2181-2187
Closed Access | Times Cited: 9
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Mohamed El‐Kassas, Abeer Awad, Mohamed Elbadry, et al.
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 054-068
Closed Access | Times Cited: 3
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Damien Chua, Zun Siong Low, Guo Xiang Cheam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14762-14762
Open Access | Times Cited: 13
Estrogen–ER‐α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women
Alessandro Cherubini, Elia Casirati, Serena Pelusi, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
PNPLA3 variation and kidney disease
Alessandro Mantovani, Giovanni Targher
Liver International (2024)
Closed Access | Times Cited: 2
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential o f Proteolysis Targeting Chimeras
Ritesh P. Bhole, S. Patil, Harshad S. Kapare, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 23, pp. 2050-2073
Closed Access | Times Cited: 2
Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy
Shahid Habib
World Journal of Gastrointestinal Pathophysiology (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 2
Fatty liver index and somatic composition in subjects receiving medical health checkup
Kosuke Ushiro, Masahiro Matsui, Akira Fukuda, et al.
Hepatology Research (2024)
Open Access | Times Cited: 2
Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele
Mélanie Kirchmeyer, Anthoula Gaigneaux, Florence Servais, et al.
Hepatology Communications (2023) Vol. 7, Iss. 12
Open Access | Times Cited: 6
Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine
Nuria Pérez-Díaz-del-Campo, Diego Martínez‐Urbistondo, Elisabetta Bugianesi, et al.
Current Opinion in Clinical Nutrition & Metabolic Care (2022) Vol. 25, Iss. 5, pp. 285-291
Closed Access | Times Cited: 7
Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
Ravi Sonkar, Hong Ma, David J. Waxman
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Investigation on the mechanism of hepatotoxicity of dictamnine on juvenile zebrafish by integrating metabolomics and transcriptomics
Xiaomin Xu, Fang Lü, Yu Wang, et al.
Gene (2024) Vol. 930, pp. 148826-148826
Closed Access | Times Cited: 1
Lipid nanosystems for fatty liver therapy and targeted medication delivery a comprehensive review
Chuipeng Liang, Xing Liu, Zihao Sun, et al.
International Journal of Pharmaceutics (2024), pp. 125048-125048
Closed Access | Times Cited: 1
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation
Matthias Ocker, Daniel Neureiter
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 12, pp. 1133-1141
Closed Access | Times Cited: 2
Fatty liver disease genetic risk variants and interference on sex hormones
Federica Tavaglione, Oveis Jamialahmadi, Luca Valenti, et al.
Liver International (2023) Vol. 43, Iss. 5, pp. 958-961
Open Access | Times Cited: 1
Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, et al.
Archives of Toxicology (2023) Vol. 97, Iss. 6, pp. 1825-1827
Open Access | Times Cited: 1

Scroll to top